ClinicalTrials.gg
CompletedNCT02578095Updated Dec 29, 2025Results posted

Acute Hip Fracture Study in Patients 65 Years or Greater

A Phase 2 interventional study of VK5211 and Placebo in Hip Fractures, sponsored by Viking Therapeutics, Inc.. Completed at 21 sites in 4 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Viking Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Hip Fractures with a site in United States — 22 open to participants now, 31 under way, none of them phase 3. Hip Fractures · United States.

Enrollment
44th of 105
108 · median 64
Started
2015
with 9 others
Phase 2
16 of 133
none open now
Registered
57th of 133
by date

Among the 133 studies in Hip Fractures with a site in United States, this one is the 44th largest by enrollment of the 105 interventional ones that give a count, is one of 10 that started in 2015, is one of 16 in phase 2, and was the 57th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

22 of the 133 studies in Hip Fractures with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Hip Fractures with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment.

Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.

03

Conditions studied

  • Hip Fractures

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females ≥65 years old who are recovering from a hip fracture (occurring 3-7 weeks prior) with no residual surgical issues will be eligible for participation.

Exclusion criteria

Exclusion Criteria:

  • Pathological fracture (e.g. fracture due to Paget's disease of bone, , etc.). Fracture due to osteoporosis is not considered pathological for this trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo QD

    Drug: Placebo

  • Experimental
    VK5211- 0.5mg

    0.5mgQD

    Drug: VK5211

  • Experimental
    VK5211- 1.0mg

    1.0mg QD

    Drug: VK5211

  • Experimental
    VK5211- 2.0mg

    2.0mg QD

    Drug: VK5211

Interventions

  • DrugVK5211

    Capsule

  • DrugPlacebo

    Capsule

06

What researchers measure

Primary outcomes

  1. Efficacy in Hip Fracture Patients Confirmed by DXA Scan.

    Efficacy of VK5211 after 12 weeks of treatment by mean placebo-corrected percentage change in total body less head (TBLH) lean body mass assessed by whole body dual-energy x-ray absorptiometry scan (DXA) scan.

    Time frame: Baseline and Week12

07

Results

Posted Dec 29, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboVK5211- 0.5mgVK5211- 1.0mgVK5211- 2.0mg
Started28292625
Completed19221717
Not completed9798

Outcome measures

PrimaryEfficacy in Hip Fracture Patients Confirmed by DXA Scan.

Efficacy of VK5211 after 12 weeks of treatment by mean placebo-corrected percentage change in total body less head (TBLH) lean body mass assessed by whole body dual-energy x-ray absorptiometry scan (DXA) scan.

Time frame:
Baseline and Week12
Reported as:
Least squares mean · PBO adjusted percent change
Efficacy in Hip Fracture Patients Confirmed by DXA Scan.
PBO adjusted percent changePlaceboVK5211- 0.5mgVK5211- 1.0mgVK5211- 2.0mg
Efficacy in Hip Fracture Patients Confirmed by DXA Scan.0 (0 to 0)4.75 (1.70 to 7.80)7.15 (3.76 to 10.54)9.08 (5.55 to 12.60)
Statistical analysis
  • Placebo vs VK5211- 0.5mg · ANCOVA · p = 0.0032 · Mean difference (final values): 4.75 · 95% CI 1.70 to 7.80
  • Placebo vs VK5211- 1.0mg · ANCOVA · p = <0.0001 · Mean difference (final values): 7.15 · 95% CI 3.76 to 10.54
  • Placebo vs VK5211- 2.0mg · ANCOVA · p = <0.0001 · Mean difference (final values): 9.08 · 95% CI 5.55 to 12.60

Adverse events

Collected over 24 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/28 (0%)4/28 (14.3%)10/28 (35.7%)
VK5211- 0.5mg0/29 (0%)2/29 (6.9%)11/29 (37.9%)
VK5211- 1.0mg0/26 (0%)3/26 (11.5%)8/26 (30.8%)
VK5211- 2.0mg0/25 (0%)5/25 (20%)16/25 (64%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboVK5211- 0.5mgVK5211- 1.0mgVK5211- 2.0mg
AnaemiaBlood and lymphatic system disorders0/280/290/261/25
PneumoniaInfections and infestations0/280/290/261/25
Femur FractureInjury, poisoning and procedural complications0/280/290/261/25
Cerebrovascular AccidentNervous system disorders0/280/290/261/25
Chronic Kidney DiseaseRenal and urinary disorders0/280/290/261/25
HaematomaVascular disorders0/280/290/261/25
Cardiac FailureCardiac disorders0/280/291/260/25
Thyroxine DecreasedInvestigations0/280/291/260/25
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/280/291/260/25
Hip FractureInjury, poisoning and procedural complications1/280/290/260/25
Most frequent other events
Showing 10 of 77
Most frequent other events
EventPlaceboVK5211- 0.5mgVK5211- 1.0mgVK5211- 2.0mg
Hepatic Enzyme IncreasedInvestigations1/281/291/264/25
AnaemiaBlood and lymphatic system disorders1/280/290/262/25
HeadacheNervous system disorders0/281/291/262/25
ContusionInjury, poisoning and procedural complications2/280/290/260/25
Cardiac Failure CongestiveCardiac disorders0/280/290/261/25
Cardiac Valve DiseaseCardiac disorders0/280/290/261/25
DiarrhoeaGastrointestinal disorders0/280/290/261/25
Dry MouthGastrointestinal disorders1/280/291/261/25
HaematocheziaGastrointestinal disorders0/280/290/261/25
NauseaGastrointestinal disorders0/280/290/261/25

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboVK5211- 0.5mgVK5211- 1.0mgVK5211- 2.0mgTotal
Median76 (64 to 91.7)78 (65 to 86)78.5 (65 to 94)78 (65 to 93.7)78 (64 to 94)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVK5211- 0.5mgVK5211- 1.0mgVK5211- 2.0mgTotal
Female1923221983
Male964625
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboVK5211- 0.5mgVK5211- 1.0mgVK5211- 2.0mgTotal
American Indian or Alaska Native00000
Asian029242578
Native Hawaiian or Other Pacific Islander00101
Black or African American10102
White2700027
More than one race00000
Unknown or Not Reported00000
08

Study locations

21 sites
  • Duurga Clinical Service
    Yorba Linda, California 92886, United States
  • Orthopedic Research Institute
    Boynton Beach, Florida 33472, United States
  • Infinite Clinical Research
    Doral, Florida 33126, United States
  • Shrock Orthopedic Research, LLC
    Fort Lauderdale, Florida 33136, United States
  • Center for Advanced Research & Education
    Gainesville, Georgia 30501, United States
  • Orthopaedic Association of Michigan
    Grand Rapids, Michigan 49525, United States
  • University of Wisconsin Osteoporosis Clinical Research Program
    Madison, Wisconsin 53705, United States
  • Szent János Kórház és Észak budai Egyesített Kórházak Traumatológiai és Kézsebészeti Osztály
    Budapest, 1125, Hungary
  • MH Egészségügyi Központ Baleseti Sebészeti Osztály
    Budapest, Hungary
  • Szent Margit Kórház, Mozgásszervi Rehabilitációs Osztály
    Budapest, Hungary
  • Petz Aladár Megyei Oktató Kórház Mozgásszervi Rehabilitációs Osztály
    Győr, 9024, Hungary
  • Jósa András Oktató Kórház Traumatológiai és Kézsebészeti Osztály
    Nyíregyháza, 4400, Hungary
  • SZTE ÁOK Traumatológiai Klinika
    Szeged, 6725, Hungary
  • Spitalul Clinic de Urgenta Bucuresti ("Floreasca")
    Bucharest, 014461, Romania
  • Spitalul Universitar de Urgenţă
    Bucharest, 050098, Romania
  • Spitalul Clinic Judeţean de Urgenţe, Sfȃntul Spiridon
    Iași, 700111, Romania
  • Institut za Ortopedsko-hirurške bolesti Banjica
    Belgrade, 11000, Serbia
  • Klinički Centar Srbije
    Belgrade, 11000, Serbia
  • Hospital Center "Bezanijska kosa" Department for Orthopedic Surgery and Traumatology
    Belgrade, 11080, Serbia
  • Clinical Center Kragujevac Department for Orthopedics and Traumatology
    Kragujevac, 34000, Serbia
  • Clinical Centre of Vojvodina Department for Orthopedic Surgery and Traumatology
    Novi Sad, 21000, Serbia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Nov 2017, 24 months.

Results were first posted in Dec 2025, 8 years 1 month after primary completion. A results delay was requested in Oct 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2015
First posted
Oct 16, 2015
StartActual
Oct 30, 2015
Primary completionActual
Nov 15, 2017
CompletionActual
Dec 17, 2017
Results delay requested
Oct 3, 2019
Results first posted
Dec 29, 2025
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02578095
Responsible party
Sponsor
First posted
Oct 16, 2015
Start date
Oct 30, 2015
Primary completion
Nov 15, 2017
Completion
Dec 17, 2017
Results posted
Dec 29, 2025
Last update
Dec 29, 2025

Study contacts

Marianne Mancini
study director · Viking Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion